Suppr超能文献

临床乳腺癌免疫组化检测的分析反应曲线

Analytic Response Curves of Clinical Breast Cancer IHC Tests.

作者信息

Vani Kodela, Sompuram Seshi R, Schaedle Anika K, Balasubramanian Anuradha, Bogen Steven A

机构信息

Medical Discovery Partners LLC, Boston, Massachusetts (KV, SRS, AKS, AB, SAB), and Department of Pathology and Laboratory Medicine, Tufts Medical Center, Boston, Massachusetts (SAB).

出版信息

J Histochem Cytochem. 2017 May;65(5):273-283. doi: 10.1369/0022155417694869. Epub 2017 Jan 1.

Abstract

An important limitation in the field of immunohistochemistry (IHC) is the inability to correlate stain intensity with specific analyte concentrations. Clinical immunohistochemical tests are not described in terms of analytic response curves, namely, the analyte concentrations in a tissue sample at which an immunohistochemical stain (1) is first visible, (2) increases in proportion to the analyte concentration, and (3) ultimately approaches a maximum color intensity. Using a new immunostaining tool ( IHControls), we measured the analytic response curves of the major clinical immunohistochemical tests for human epidermal growth factor receptor type II (HER-2), estrogen receptor (ER), and progesterone receptor (PR). The IHControls comprise the analytes HER-2, ER, and PR at approximately log concentration intervals across the range of biological expression, from 100 to 1,000,000 molecules per test microbead. We stained IHControls of various concentrations using instruments, reagents, and protocols from three major IHC vendors. Stain intensity at each analyte concentration was measured, thereby generating an analytic response curve. We learned that for HER-2 and PR, there is significant variability in test results between clinical kits for samples with analyte concentrations of approximately 10 molecules/microbead. We propose that the characterization of immunostains is an important step toward standardization.

摘要

免疫组织化学(IHC)领域的一个重要局限是无法将染色强度与特定分析物浓度相关联。临床免疫组织化学检测并未按照分析反应曲线进行描述,也就是说,未描述组织样本中分析物浓度与免疫组织化学染色之间的关系,即(1)染色首次可见时的分析物浓度,(2)染色强度随分析物浓度成比例增加,以及(3)最终接近最大颜色强度时的分析物浓度。我们使用一种新的免疫染色工具(IHControls),测量了针对人表皮生长因子受体2型(HER-2)、雌激素受体(ER)和孕激素受体(PR)的主要临床免疫组织化学检测的分析反应曲线。IHControls包含HER-2、ER和PR分析物,在每个测试微珠上,其浓度范围跨越生物表达范围,以大约对数浓度间隔分布,从每微珠100到1,000,000个分子。我们使用来自三家主要免疫组织化学供应商的仪器、试剂和方案,对不同浓度的IHControls进行染色。测量每个分析物浓度下的染色强度,从而生成分析反应曲线。我们发现,对于HER-2和PR,分析物浓度约为10个分子/微珠的样本,临床试剂盒之间的检测结果存在显著差异。我们认为免疫染色特性的表征是迈向标准化的重要一步。

相似文献

1
Analytic Response Curves of Clinical Breast Cancer IHC Tests.临床乳腺癌免疫组化检测的分析反应曲线
J Histochem Cytochem. 2017 May;65(5):273-283. doi: 10.1369/0022155417694869. Epub 2017 Jan 1.

引用本文的文献

2
A Consortium for Analytic Standardization in Immunohistochemistry.免疫组织化学分析标准化联合会。
Arch Pathol Lab Med. 2022 May 1;147(5):584-590. doi: 10.5858/arpa.2022-0031-RA.
6
A Root Cause Analysis Into the High Error Rate in Clinical Immunohistochemistry.临床免疫组织化学高错误率的根本原因分析
Appl Immunohistochem Mol Morphol. 2019 May/Jun;27(5):329-338. doi: 10.1097/PAI.0000000000000750.

本文引用的文献

4
Quantification of HER family receptors in breast cancer.乳腺癌中HER家族受体的定量分析。
Breast Cancer Res. 2015 Apr 9;17:53. doi: 10.1186/s13058-015-0561-8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验